Abstract: Nasal high flow (NHF) is a promising novel oxygen delivery device, whose mechanisms of action offer some beneficial effects over conventional oxygen systems. It is considered to have a number of physiological effects: it improves oxygenation, dynamic lung compliance, homogeneity and end expiratory lung volume; it decreases anatomical dead space and generates a positive airway pressure that can reduce respiratory rate, the work of breathing, and enhance patient comfort. NHF has been used as a prophylactic tool or as a treatment device mostly in patients with acute hypoxemic respiratory failure such as preoxygenation before intubation, immunocompromised patients and acute heart failure. Moreover, there is some evidence that NHF could be used during procedural sedation. Finally, NHF was deemed to be effective in chronic obstructive pulmonary disease patients with its positive end expiratory pressure effects and dead-space washout. However, careful monitoring is crucial to maximize NHF settings aimed at maximizing patient comfort while limiting the risk of delayed intubation. The present review presents the most updated evidence for NHF use in the adult acute care setting with the goal of providing clinicians with useful insights on the physiologic effects, main clinical indications, and safety issues of NHF treatment. Keywords: nasal high flow, physiological effects, positive end-expiratory, acute respiratory failure, oxygenation therapy Introduction Nasal high flow (NHF) is a noninvasive respiratory support designed to deliver 30-60 L/minute of a heated, humidified mixture of air and oxygen through specifically designed nasal prongs. NHF allows modification of two main settings-the percentage of oxygen delivered and the rate of gas flow. NHF can deliver a mix of air and oxygen with an inspired oxygen fraction (FiO 2 ) ranging between 0.21 and 1.0 and the flow rate ranges from 30 to 60 L/minute. Thus, NHF is not necessarily a very high flow of pure oxygen as often wrongly referred to in previous publications. Recently, NHF has gained increasing popularity in treating both type I (hypoxemic) and type II (hypoxemic/hypercapnic) acute respiratory failure (ARF) globally. However, the physiologic effects of NHF on the respiratory system function, and its influence on clinical outcomes are still open research fields, with new studies being published every week or so. The present review presents the most updated evidence for NHF use in the adult acute care setting (ie, from the emergency department to the intensive care unit, ICU) with the goal of providing clinicians with useful insights on the physiologic effects, main clinical indications and safety issues of NHF treatment.
Introduction Physiological effects
The main physiological effects of NHF are maintenance of a known stable alveolar FiO 2 , optimal humidification of the airway mucosa, reduction of the dead space, generation of a positive end-expiratory pressure (PEEP), ultimately yielding a reduction in the respiratory drive and in the work of breathing (see Table 1 ).
Stable alveolar FiO 2
Low-flow nasal cannulas are connected to the hospital gas delivery system via flowmeters, most of which allow delivery of gas flows up to 15 L/minute. Traditional nasal cannula flow rate has been limited, not only due to the internal diameter of the cannula, but also by the risks associated with the lack of heating and humidification of the inspired gas. In dyspneic ARF patients, when the inspiratory flow rate exceeds the flow delivered, additional flow is entrained from the surrounding room air. Consequently, traditional low flow nasal cannula cannot deliver constant alveolar FiO 2 , even at the highest flow rates.
1,2 NHF very high flow rates can match the inspiratory demand of dyspneic patients and overcome the need of additional room air-mixing, finally providing stable delivered alveolar FiO 2 . 3 In the abovementioned range from 30 to 60 L/minute, bench studies showed that the FiO 2 measured in distal airways is very close to the set FiO 2 . 4 Recently, Parke et al 5 performed a study on healthy volunteers with NHF delivered with flow exceeding 60 L/ minute. If heating and humidification can be granted as such high flow rates, this study suggests that alveolar FiO 2 during NHF could be high and stable even in the most severe patients. NHF, in the presence of stable oxygen consumption and CO2 production, likely improves the correspondence between set and alveolar FiO2, but the extent of this benefit is difficult to predict in clinical practice.
Humidification
Conventional oxygen devices delivering dry and cold gases usually causes discomfort, nasal and oral dryness, Table 1 Key physiological benefits of NHF, divided between those already described in recent literature and still to be assessed in prospective studies
Key physiological benefits of NHF 
Still hypothetical
Improved matching between set and alveolar FiO 2
Optimization of mucociliary cells function Reduced CO 2 production from mucosal epithelium and inspiratory muscles 
Reduction of respiratory drive
Nearly all studies conducted both in healthy volunteers and in ARF patients reported decreased respiratory rate and improved dyspnea during NHF compared to standard low-flow oxygen. These findings suggest that the central respiratory drive could be reduced by NHF, likely through the interaction between all the abovementioned mechanisms: increased alveolar FiO 2 could lead to improved oxygenation and decreased hypoxic drive, effective humidification could reduce discomfort, dead space washout reduces the minute ventilation needed to maintain stable arterial CO 2 level and the hypercapnic drive, and finally the PEEP effect could contribute to improved oxygenation and to improved respiratory system mechanics with easier ability to inspire the desired Vt.
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Reduction of work of breathing NHF could also decrease the work of breathing, depending on the clinical condition of the patient. Sztrymf et al 22 showed an improvement in subjective measures of inspiratory load by NHF in the patients diagnosed as having poor thoraco-abdominal coordination under standard low-flow oxygen. The same results were obtained by Itagaki et al 23 in patients with mild to moderate respiratory failure treated with the NHF after thoracotomy. Previous studies also described the reduction of inspiratory effort and work of breathing by NHF, as quantified by esophageal pressure inspiratory swings in pediatric populations. 9, 24 Mauri et al 25 performed a prospective randomized crossover study in adults nonintubated patients with hypoxemic ARF.
Measures of inspiratory effort and metabolic work of breathing assessed by esophageal pressure significantly decreased during NHF therapy ( Figure 1 ). The authors also suggested that NHF could improve other key physiologic parameters including dynamic lung compliance, transpulmonary pressure, and homogeneity. Similar effects on reduction of effort and work of breathing were reported in stable patients with COPD (see the section below).
Clinical indications in hypoxemic patients
Acute hypoxemic respiratory failure NHF is becoming the first-line treatment for acute hypoxemic respiratory failure (AHRF) patients when standard oxygenation via facial mask or nasal cannula yields poor oxygenation and immediate intubation is not required. The benefits of NHF therapy compared to standard oxygen has been widely described since the first study of Roca et al 26 in adult patients in 2010. It reported an increase in both SaO 2 and PaO 2 and comfort with a decrease of respiratory rate and dyspnea. These results were further confirmed by Sztrymf et al 27 who also reported important hints on early recognition of NHF failure and the need for consideration for intubation. 22 Compared to conventional oxygen therapy, NHF could be more effective in mild to moderate AHRF also in reducing the need for escalation to noninvasive ventilation (NIV). 28 But it was not until the first large randomized clinical trial by Frat et al, 29 the FLORALI trial, that NHF administered at 50 L/minute was compared both to NIV (for at least 8 hours per day) and standard oxygen (face mask at 10 L/minute or more) in terms of hard clinical outcomes.
In patients with a PaO 2 /FiO 2 ratio ≤300 with AHRF (84% with pneumonia as primary diagnosis), NHF was not superior to the other two treatments in lowering intubation rate, the primary outcome. However, a post-hoc analysis found that NHF significantly reduced intubation in the subgroup with PaO 2 /FiO 2 ratio ≤200. Ventilatorfree days and 90 day mortality, described as secondary outcomes, were reduced by NHF in the whole population, too. These results were challenged by a second large randomized clinical trial, the HOT-ER trial, 30 comparing the administration of NHF starting from 30 L/minute to face mask oxygenation up to 15 L/minute in the emergency department. NHF resulted in lower rates of intubation after 24 hours (although with a marginal statistical significant, P=0.053). No differences in mortality at 90 days was found. However, HOT-ER population was different and very heterogeneous, with lower percentage of community acquired pneumonia patients and without the exclusion of COPDand asthma exacerbations. Two recent systematic reviews and meta-analyses were published to better clarify these aspects. The first included over 3,000 AHRF patients and described that NHF reduced the need for endotracheal intubation compared to conventional oxygen and NIV (OR: 0.60, 95%CI:0.41-0.86). 31 The second 32 included 1,084
patients and reported that, compared to conventional oxygen and NIV, NHF could reduce both the rate of endotracheal intubation (OR: 0.62 and OR: 0.48, respectively) and ICU mortality (OR: 0.47 and OR: 0.36, respectively) when used before mechanical ventilation.
Although still relatively few, these data seem to indicate that NHF should be considered as first-line therapy for patients with AHRF.
Acute hypoxemic respiratory failure in immunosuppressed patients
Intubation in immunosuppressed patients with AHRF is associated with extremely elevated mortality, hence a respiratory management aiming to avoid intubation should be promoted.
A post-hoc analysis of the FLORALI trial showed that NIV increased intubation and mortality compared to NHF or conventional oxygen in immunosuppressed patients. 33 The same results were obtained in a prospective observational study with NHF compared to NIV, both used as firstline therapy. 34 Moreover, NHF compared to NIV and face mask oxygen, respectively, was associated with lower mortality in specific cohorts, such as cancer patients 35 and lung transplantrecipients. However, the population was very heterogeneous and the authors concluded that attention to oxygenation strategies may not be the main focus in such a diverse population.
Preoxygenation for intubation
The main goal of preoxygenation is to extend the period of safe apnea, thus avoiding a desaturation below 88% during intubation manuever. This is usually achieved by obtaining an arterial oxyhemoglobin saturation as close as possible to 100% and by the denitrogenation of the lungs (ie, the wash out of nitrogen contained in room air, increasing alveolar oxygen reservoir). These aspects might be both promoted by the dead-space washout and PEEP effect of the NHF therapy. Moreover, compared to other facial devices, NHF support can be kept during the maneuver. In the operating theatre, preoxygenation with NHF was applied to a cohort of 50 patients undergoing scheduled awake fiberoptic intubation for expected difficult airways management. The therapy was generally well tolerated, with no desaturation below 90% despite the length of procedures (up to 17 minutes). 38 In the same clinical setting, NHF at 70 L/minute for 10 minutes during induction was tested to deliver apneic oxygenation: Patel et al 39 associated NHF oxygenation to jaw thrust to increase apnea time during induction of general anesthesia and difficult airways management with no desaturation and stable CO 2 level. These results were further confirmed by a randomized clinical trial, highlighting NHF potential compared to face mask during preoxygenation for rapid sequence induction of anesthesia. 40 In critically ill patients, given the possible combination of reduced pulmonary functional residual capacity and a compromised cardiovascular reserve, achieving an optimal oxygenation status during intubation is mandatory. Despite preliminary promising evidences, 41 preoxygenation by NHF did not prevent occurrence of severe hypoxemia compared to standard clinical practice (ie administering oxygen through a non-rebreathing bag reservoir facemask) 42 irrespective of baseline patients' oxygenation status. 43 It could be inferred that in patients with AHRF as primary reason for intubation, the PEEP and the apneic oxygenation effects induced by NHF might not avoid desaturation. Conversely, NIV effectiveness has been proved for preoxygenation in patients with severe AHRF. 44 Moreover, the combination of NHF with NIV seems to maintain higher SpO 2 levels during induction with no severe desaturation (SpO 2 <80%) compared to NIV alone, since NHF and apneic oxygenation can be continued after NIV is removed. 45 The final word on NHF vs NIV for preoxygenation in AHRF critically ill patients might come from ongoing trials. 46 Acute heart failure Through the generation of low levels of PEEP and improved oxygenation, HFNC resulted in positive hemodynamic changes in New York Heart Association class III patients as indicated by significantly decreased inspiratory collapse of the inferior vena cava and thus the preload of the right ventricle. 47 Consequently, NHF therapy seems promising in acute cardiogenic pulmonary edema. However, limited evidence exists on its application in this context: Carratala Perales et al 48 showed significant improvement of the intensity of dyspnea, respiratory rate and oxygenation after 24 hours of HFNC treatment in 5 patients with acute heart failure and refractory hypoxemia despite NIV. To date, no randomized clinical trial has been published comparing NHF with NIV or standard oxygen in acute heart failure or acute myocardial infarction patients.
Procedural sedation
Procedural sedation is widely used to achieve safe adequate patient tolerance of several invasive procedures in the respiratory medicine, interventional gastroenterology, and cardiology fields. Due to the expected side effects of the sedative drugs (eg, propofol, benzodiazepines, opioids), the respiratory drive is depressed, reflexes are inhibited and upper airways might be occluded. Hence, oxygen saturation may fall despite oxygen supplementation. NHF has been proposed as an ideal oxygenation device since it allows oral passage of the operative tools while improving oxygenation during the procedure through PEEP effect and additional oxygen. Lucangelo et al prospectively randomized 45 nonhypoxemic patients undergoing bronchoscopy to NHF set at 40 L/minute with 50% FiO 2 , NHF set at 60 L/minute with 50% FiO 2 , or Venturi mask with 50% FiO 2 during the procedure. 49 With similar sedative drugs dosage and procedure duration among groups, NHF set at 60 L/minute granted more adequate oxygenation (higher SpO 2 and PaO 2 /FiO 2 compared to the other treatments) at the end and shortly after the procedure, thus being a reasonable option during routine bronchoscopy in patients with mild respiratory dysfunction. Simon et al 50 compared the use of NHF at 50 L/min to NIV in critically ill patients with moderate to severe hypoxemia during bronchoscopy: patients treated with NIV showed better oxygenation during and after the procedure, however patients treated by NHF maintained acceptable peripheral oxygenation throughout the procedure (minimum value 92±7%). In a similar cohort of patients, La Combe et al 51 tested the efficacy of NHF therapy at 50-60 L/min with only 5/30 patients requiring escalation of therapy within 24 hrs after bronchoscopy. These studies suggest the efficacy and safety of NHF during bronchoscopy also in patients with compromised respiratory function. NHF therapy seems promising as respiratory support also in procedural sedation during dental surgery, 52 and during percutaneous balloon aortic valvuloplasty under continuous monitoring with transesophageal echocardiography. 53 Finally, in a retrospective analysis of 238 patients undergoing endoscopic retrograde cholangiopancreatography, 54 NHF use during deep sedation might be useful to avoid general anesthesia in those patients considered at high risk of perioperative mortality.
Clinical indications for COPD patients
According to the World Health Organization, 65 million people worldwide suffer from moderate to severe COPD, which is supposed to become the third leading cause of death by 2020. 55, 56 NIV is the first-line respiratory support for hypercapnic ARF. However, it is applied intermittently, usually with periods of unsupported spontaneous breathing with conventional O 2 interspersed between NIV sessions. Standard O 2 has several drawbacks that may limit the benefit of intermittent NIV in hypercapnic ARF: limited gas flow; cold and dry gases leading to discomfort and under-humidification. In this scenario, the role of NHF could open new perspectives in the management of both acute and chronic hypercapnic COPD patients, when applied during breaks from NIV, and a dedicated study might unveil the advantages of NHF support soon. 57 During COPD both lung compliance and airway resistance increase and the physiologic breathing pattern with lower respiratory rate and higher variability could be beneficial in COPD patients. In COPD patients, the PEEP generated by NHF could stent the early-collapsing bronchioles, counterbalancing-at least in part-the intrinsic positive end-expiratory pressure (PEEPi), and improving the alveolar gas exchange (both hypoxia and hypercapnia). As the end-expiratory airway pressure is increased by NHF, the work of breathing needed to overcome both elastic and resistive components is lower for the same tidal volume. Being the initial airway pressure higher with the small PEEP generated by NHF, the work of breathing, which should overcome both elastic and resistive components of the lung, is lower for the same tidal volume during NHF . More than the PEEP effect, two major mechanisms of NHF can provide a strong pathophysiological rationale for its application in hypercapnic COPD patients: (1) the reduction of work of breathing via the reduction of inspiratory resistance: as the upper airway resistance from nares to trachea constitutes about two thirds of total airway resistance, NHF reaches past the nasal valve leading to a significant reduction of inspiratory work of breathing. As is well documented in an elegant study by Adams et al, 58 during the inspiratory phase, NHF rates elevate tracheal pressure, but the latter reaches more rapidly the zero and negative pressure; then, from this point and until the end of inspiration, no muscular efforts are spent to overcome the upper airway resistance; (2) the washout of upper airways dead space. Recently, Biselli et al have reported that in COPD patients during sleep, the degree of physiological dead space at baseline correlates with its reduction during NHF. 59 Interestingly, the reduction in minute ventilation observed during NHF was due to a reduction of Vt without changes in RR apart from one case. It is important to underline that despite the decrease of Vt, NHF was associated to a significant reduction in transcutaneous CO 2 , indicating higher efficiency of the minute ventilation.
Acute hypercapnic respiratory failure
Kim et al performed a single center retrospective study on thirty-tree patients admitted to the medical intensive care unit for ARF with hypercapnia (PaCO 2 56.3±10.7 mmHg) and treated with conventional oxygen therapy (COT) or NIV. 60 NHF was applied when the patients did not improve or for intolerance to NIV. Once started, NHF decreased PaCO 2 after both 1 and 24 hours of treatment, resulting in a significant improvement of hypercapnia; furthermore, NHF efficacy was irrespective of whether chronic hypercapnia was present or not. However, a similar decrease in PaCO 2 was obtained with COT and NIV, too. It should be noted that patients in this study might have already achieved a clinical stability when started on NHF, as indicated by the absence of respiratory acidosis despite hypercapnia (mean PaCO 2 mmHg, but mean normal pH was 7.37). Thus, we cannot exclude that the initial treatment with NIV or simply the medical therapy was the determinant of hypercapnia correction, independently from the type of respiratory support. Furthermore, NHF was applied if no clinical improvement with COT or NIV was observed, but "no clinical improvement" does not necessarily mean "clinical failure". Finally, the etiology of respiratory failure was extremely heterogeneous (pneumonia, acute exacerbation of COPD, worsening of interstitial lung disease, cardiogenic edema, extrapulmonary acute lung injury) and no clinical severity score was reported. The study by Kim et alshowed feasibility of NHF as an alternative to COT and NIV in stable COPD patients. In another prospective observational trial, 61 Lee et alcompared the effectiveness of NHF and NIV for the treatment of severe acute exacerbation of COPD (AECOPD) with moderate hypercapnia. The primary endpoint was the intubation rate and 30-day mortality. The The clinical efficacy and safety of NHF compared to low-flow oxygen via nasal cannulae or mask, continuous positive airway pressure and bi-level positive airway pressure, in adult COPD patients hospitalized in the ICU, were analysed in the 2017 Cochrane systematic review. Pooled data analysis revealed no differences in carbon dioxide clearance between groups. 62 Finally, in a large multicenter randomized trial on adults presenting to the emergency department with mixed hypoxemic or hypercapnic respiratory failure requiring noninvasive ventilation, 63 patients were randomly assigned to receive NHF or NIV. The study evidenced similar improvement in the PaCO 2 levels over time in both arms, in the whole population and in the subgroup with initial PaCO 2 greater than 45 mmHg. These studies indicate that NHF is feasible and safe in the treatment of AECOPD patients and might be correlated with improved physiology, like NIV but with a much easier setup. Well conducted randomized trials in AECOPD comparing the clinical efficacy of HFNC vs COT or NIV are still lacking. The etiology of hypercapnia should become a more central focus to move forward with future studies.
NHF in the emergency department
The use of NHF has been reported in the whole spectrum of the critical care settings, including ICUs and perioperative medicine, both for hypoxic and hypercapnic ARF. There issome initial evidence on the use of NHF in patients admitted to the emergency department (ED) with dyspnea, too. A prospective, observational study was conducted in the ED by Lenglet et al. 64 Their study showed physiological improvements of dyspneic patients by NHF, such as decreased RR, and dyspnea scores and increased SpO 2 . Bell et al 65 enrolled 100 patients presenting at the ED with shortness of breath in a randomized controlled trial comparing NHF with conventional O 2 . They described that the use of NHF was associated with greater reduction in RR (>20% from baseline) and lower need for escalation of respiratory support. These results suggest that use of NHF is feasible and effective in the ED and could be considered first-line support in patients with acute shortness of breath. Makdee et al 66 also
found that NHF may decrease the severity of dyspnea during the first hour of treatment in ARF due to congestive heart failure in the ED, compared to COT. Since these data are not sufficient to define feasibility and efficacy of NHF in patients presenting with ARF at the ED, a few concerns should be brought to the attention of emergency physicians. 67 When a patient is admitted to the ED, the primary aim of the attending physician should be to perform accurate diagnosis. Before starting NHF, several aspects of the patient's condition should be evaluated, including severity of illness and need for ICU admission. Indeed, NHF can mask severe conditions, delaying diagnosis and escalation of treatment. Initial NHF settings could be based on diagnosis, too, as more hypoxic patients or those with acute cardiogenic pulmonary edema could benefit more from higher flow rate, while a lower rate could be selected in hypercapnic ones. During NHF support, it is important to frequently reevaluate respiratory parameters, including RR, SpO 2 , dyspnea score and comfort to detect early NHF failure. 68 
Safety issues during NHF support
One of the main concern during NHF support is the risk of delayed endotracheal intubation in hypoxemic patients. In a retrospective observational study, Kang et al 69 showed
how NHF might unduly delay initiation of mechanical ventilation and worsen patient outcome. They reported that patients intubated after 48 hours from HFNC initiation had higher overall ICU mortality after propensity score adjustment and matching vs patients intubated within 48 hours. However, the criteria for intubation were not prospectively standardized and the patients with delayed intubation might have simply been overlooked by the staff physicians. 70 Moreover, in the Kang et al study, median duration of NHF support in the group intubated after more than 48 hours was 126 hours in comparison with 10 hours in the <48 hours group. This induced Ricard et al 71 to ask whether leaving patients in respiratory distress for more than 5 days, with all the associated clinical implications, could have had a major impact on ICU mortality. Still, failure to improve within 48 hours should be seen as a sign of more severe lung injury. To this end, Roca et al 72, 73 proposed a new index, the ROX index, calculated as (SpO 2 /FiO 2 )/RR, to identify at 12 hours the patients at higher risk of NHF failure. A ROX index ≥4.88 points can identify patients who will likely heal, while ROX <3.85 is associated with high probability of ending up intubated. Other signs of respiratory distress such as respiratory rate, use of accessory respiratory muscles, presence of thoraco-abdominal asynchrony and discomfort measured within the first hour ofNHF initiation were associated with high risk of failure. 27, 74 Together with the abovementioned clinical parameters, the radiological analysis of chest X-ray has been considered to predict failure. Koga et al 75 described that the extent of pleural effusion at NHF initiation was associated with failure. Lung imaging (ie chest X-ray, lung ultrasound or EIT) could have an important role in the early identification of patients with extensive opacities or effusions and eventually failing NHF.
Major safety issues associated with use of NHF in the neonatal population, such as pneumothorax or burn lesions, are not reported in adults. However, another drawback might be severe patient discomfort. In a recent posthoc analysis of the FLORALI trial, Frat et al 74 reported
higher patient discomfort after 1 hour in patients failing NHF support vs those who were not intubated. Patient discomfort might be also linked to insufficient air humidification/high temperature. Mauri et al 76 reported
that, independently from the set flow rate, lower temperature with full humidification is associated with lower discomfort.
In a study performed in the ED, 64 both patients (100%) and caregivers (82%) judged NHF to be more comfortable compared to standard oxygenation therapy. In the same study, noise level generated by NHF (55 dB) was comparable to standard oxygen face mask (50 dB) and not higher than ambient noise (60-70 dB). Altogether, 76% of caregivers preferred NHF, compared to COT. Available data in recent literature indicates that, despite the significant advantages provided by NHF to the management of ARF patients, around 30% of them will fail and require invasive ventilation. Hence, ED physicians should keep in mind that patients presenting higher complexity should be monitored closely, for example presence of an additional extrapulmonary organ failure is an early indicator of risk of failure. 77 In another study, Messika et al 78 reported that in a cohort of ARF patients the Simplified Acute Physiology Score II was higher in patients failing NHF, mostly due to additional hemodynamic and neurologic dysfunctions. Roca et al, 36 in a cohort of lung transplant recipients re-admitted to the ICU and supported by NHF, found that patients with bilateral infiltrates and those needing vasopressors during their ICU stay were more likely to end up intubated. Consistent with these results was the finding by Koga et al 75 of a higher sequential organ failure assessment score in ARF patients failing NHF, with similar relevance for all the components of the score.
Conclusion
NHF is a powerful noninvasive respiratory support that can positively impact the physiology of acute and chronic respiratory failure patients. However, studies showing translational benefits on hard clinical outcomes are still to come in most patient populations. Careful monitoring is crucial to maximize NHF benefits while limiting the risk of delayed intubation.
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